JNP - Juniper Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
8.60
-0.15 (-1.71%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close8.75
Open8.70
Bid0.00 x 0
Ask0.00 x 0
Day's Range8.50 - 8.75
52 Week Range3.65 - 8.95
Volume38,165
Avg. Volume48,877
Market Cap93.259M
Beta1.64
PE Ratio (TTM)13.78
EPS (TTM)0.62
Earnings DateNov 13, 2017 - Nov 17, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.00
Trade prices are not sourced from all markets
  • Juniper Pharmaceuticals to Explore Strategic Alternatives
    PR Newswire22 days ago

    Juniper Pharmaceuticals to Explore Strategic Alternatives

    BOSTON, Jan. 31, 2018 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. ("Juniper" or the "Company") (JNP), a diversified healthcare company focused on women's health, today announced that it is exploring strategic alternatives in order to enhance shareholder value. The Company has engaged Rothschild as its independent financial advisor to assist Juniper and its Board of Directors in evaluating potential strategic alternatives. "Over the past year, we have made important investments into our core businesses, Juniper Pharma Services and Crinone®, that supported strong double-digit revenue growth and established a strong financial foundation for Juniper," said Alicia Secor, Juniper's President and CEO.

  • Juniper Pharmaceuticals Announces 4.5-Year Extension through 2024 of CRINONE® Supply Agreement with Merck KGaA, Darmstadt, Germany
    PR Newswirelast month

    Juniper Pharmaceuticals Announces 4.5-Year Extension through 2024 of CRINONE® Supply Agreement with Merck KGaA, Darmstadt, Germany

    BOSTON, Jan. 8, 2018 /PRNewswire/ -- Juniper Pharmaceuticals (JNP), a diversified healthcare company focused on women's health, today announced the extension of its supply agreement for CRINONE® (progesterone gel) with an affiliate of Merck KGaA, Darmstadt, Germany. Merck KGaA, Darmstadt, Germany has marketing rights worldwide except the United States, where CRINONE® is marketed by Allergan plc. "Our longstanding collaboration with Merck KGaA, Darmstadt, Germany to supply CRINONE® progesterone gel for sale outside of the U.S. remains an extremely important core business for us.

  • Juniper Pharmaceuticals Outlines Strategic Priorities for 2018 and Reports Recent Portfolio Progress
    PR Newswire2 months ago

    Juniper Pharmaceuticals Outlines Strategic Priorities for 2018 and Reports Recent Portfolio Progress

    BOSTON, Jan. 2, 2018 /PRNewswire/ -- Juniper Pharmaceuticals (JNP), a diversified healthcare company focused on women's health, today provided financial guidance for 2018, reflecting continued strength in the Company's core businesses, Juniper Pharma Services (JPS) and CRINONE® (progesterone gel), and provided an overview of strategic priorities for 2018. The Company also announced positive top-line pharmacokinetic data from in vivo animal studies evaluating each of the Company's three IVR formulations.

  • Juniper Pharma Services' co-founder awarded CBE in the Queen's New Year's Honours List
    PR Newswire2 months ago

    Juniper Pharma Services' co-founder awarded CBE in the Queen's New Year's Honours List

    BOSTON, Dec. 29, 2017 /PRNewswire/ -- Juniper Pharmaceuticals (JNP), a diversified healthcare company focused on women's health, today announced that Juniper Pharma Services co-founder Martyn Davies, PhD, has been appointed as a Commander of the Order of the British Empire (CBE) in Her Majesty's 2018 New Year's Honours List. Dr. Davies will officially receive his CBE medal at an Investiture in 2018. Dr. Davies has been granted one of the United Kingdom's most prestigious awards in recognition of his contribution to science and his ground-breaking achievements in pharmaceutical research and drug development.

  • Juniper Pharmaceuticals Inc (NASDAQ:JNP): What’s The Analyst Consensus Outlook?
    Simply Wall St.2 months ago

    Juniper Pharmaceuticals Inc (NASDAQ:JNP): What’s The Analyst Consensus Outlook?

    In September 2017, Juniper Pharmaceuticals Inc (NASDAQ:JNP) announced its most recent earnings update, which confirmed that the business turned profitable again after incurring losses in the last financial year. Below,Read More...

  • Capital Cube3 months ago

    ETFs with exposure to Juniper Pharmaceuticals, Inc. : December 1, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Juniper Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to JNP-US. Comparing the performance and risk of Juniper Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Capital Cube3 months ago

    ETFs with exposure to Juniper Pharmaceuticals, Inc. : November 20, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Juniper Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to JNP-US. Comparing the performance and risk of Juniper Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Is Juniper Pharmaceuticals Inc’s (JNP) PE Ratio A Signal To Buy For Investors?
    Simply Wall St.3 months ago

    Is Juniper Pharmaceuticals Inc’s (JNP) PE Ratio A Signal To Buy For Investors?

    Juniper Pharmaceuticals Inc (NASDAQ:JNP) trades with a trailing P/E of 7.6x, which is lower than the industry average of 23.5x. While this makes JNP appear like a great stock toRead More...

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of JNP earnings conference call or presentation 2-Nov-17 8:30pm GMT

    Q3 2017 Juniper Pharmaceuticals Inc Earnings Call

  • Juniper Pharmaceuticals, Inc. :JNP-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017
    Capital Cube4 months ago

    Juniper Pharmaceuticals, Inc. :JNP-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017

    Categories: Yahoo FinanceGet free summary analysis Juniper Pharmaceuticals, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Juniper Pharmaceuticals, Inc. – Abbott Laboratories, Johnson & Johnson and Pfizer Inc. (ABT-US, JNJ-US and PFE-US) that have also reported for this period. Highlights Summary numbers: Revenues of ... Read more (Read more...)

  • Flavor Of The Month: Net 1 UEPS Technologies And More
    Simply Wall St.4 months ago

    Flavor Of The Month: Net 1 UEPS Technologies And More

    Undervalued companies, such as Net 1 UEPS Technologies and Juniper Pharmaceuticals, are those that trade at a price below their actual values. Investors can profit from the difference by investingRead More...

  • Juniper Pharmaceuticals Reports Third Quarter 2017 Financial and Operating Results
    PR Newswire4 months ago

    Juniper Pharmaceuticals Reports Third Quarter 2017 Financial and Operating Results

    CRINONE® Revenues Increased 19% and Juniper Pharma Services Revenues Increased 38% Year-over-Year Implemented Strategic Reprioritization BOSTON , Nov. 2, 2017 /PRNewswire/ -- Juniper Pharmaceuticals (Nasdaq: ...

  • PR Newswire4 months ago

    Juniper Pharmaceuticals to Report Third Quarter 2017 Results on November 2, 2017

    Conference Call Scheduled for 4:30 p.m. EDT BOSTON , Oct. 26, 2017 /PRNewswire/ -- Juniper Pharmaceuticals (Nasdaq: JNP) ("Juniper" or the "Company"), will hold a conference call on ...

  • Juniper Pharmaceuticals Inc (JNP) Delivered A Better ROE Than The Industry, Here’s Why
    Simply Wall St.4 months ago

    Juniper Pharmaceuticals Inc (JNP) Delivered A Better ROE Than The Industry, Here’s Why

    With an ROE of 22.44%, Juniper Pharmaceuticals Inc (NASDAQ:JNP) outpaced its own industry which delivered a less exciting 18.27% over the past year. On the surface, this looks fantastic sinceRead More...

  • Juniper Pharmaceuticals, Inc. :JNP-US: Earnings Analysis: Q2, 2017 By the Numbers : September 20, 2017
    Capital Cube5 months ago

    Juniper Pharmaceuticals, Inc. :JNP-US: Earnings Analysis: Q2, 2017 By the Numbers : September 20, 2017

    Categories: Yahoo FinanceGet free summary analysis Juniper Pharmaceuticals, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Juniper Pharmaceuticals, Inc. – Agile Therapeutics, Inc., Akorn, Inc., TherapeuticsMD, Inc. and Pfizer Inc. (AGRX-US, AKRX-US, TXMD-US and PFE-US) that have also reported for this period. Highlights Summary ... Read more (Read more...)

  • Juniper Pharmaceuticals Announces Strategic Reprioritization
    PR Newswire5 months ago

    Juniper Pharmaceuticals Announces Strategic Reprioritization

    BOSTON, Sept. 18, 2017 /PRNewswire/ -- Juniper Pharmaceuticals (JNP), a women's health therapeutics company, today announced a corporate reprioritization to allow the Company to focus its resources on the core businesses of Crinone® progesterone gel and Juniper Pharma Services (JPS), both of which continue to drive strong double-digit annual growth. As part of this initiative, the Company will begin to focus its research and development organization on JNP-0201 for hormone replacement therapy (HRT) as the Company's potential lead intravaginal ring (IVR) program and seek to potentially partner its other IVR programs.

  • Juniper Pharmaceuticals Appoints Jennifer Good to Board of Directors
    PR Newswire5 months ago

    Juniper Pharmaceuticals Appoints Jennifer Good to Board of Directors

    BOSTON, Sept. 11, 2017 /PRNewswire/ -- Juniper Pharmaceuticals (JNP), a women's health therapeutics company, today announced the appointment of Jennifer Good to the Company's Board of Directors. Ms. Good will serve as a member of both the Audit Committee and Compensation Committee. "We are excited to have Jennifer join the Juniper team.

  • Thomson Reuters StreetEvents6 months ago

    Edited Transcript of JNP earnings conference call or presentation 3-Aug-17 8:30pm GMT

    Q2 2017 Juniper Pharmaceuticals Inc Earnings Call

  • Associated Press7 months ago

    Juniper Pharmaceuticals posts 2Q loss

    On a per-share basis, the Boston-based company said it had a loss of 3 cents. The pharmaceutical company posted revenue of $14 million in the period. In the final minutes of trading on Thursday, the company's ...

  • Juniper Pharmaceuticals Reports Second Quarter 2017 Financial and Operating Results
    PR Newswire7 months ago

    Juniper Pharmaceuticals Reports Second Quarter 2017 Financial and Operating Results

    CRINONE® Revenues Increased 30% and Juniper Pharma Services Revenues increase 30% Year-over-Year BOSTON , Aug. 3, 2017 /PRNewswire/ -- Juniper Pharmaceuticals (Nasdaq: JNP), a women's health therapeutics ...

  • ACCESSWIRE7 months ago

    Investor Network: Juniper Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 3, 2017 / Juniper Pharmaceuticals, Inc. (NASDAQ: JNP ) will be discussing their earnings results in their Q2 Earnings Call to be held on Thursday, August 03, 2017 at ...